DIGITAL DOMAIN (00547) releases annual performance, showing a net loss of HK$257 million for shareholders, a decrease of 14.3% year-on-year.
Digital Kingdom (00547) released its annual performance for the year ended December 31, 2025, with revenue of 777 million Hong Kong dollars, a year-on-year increase of 24.2%. The company's net loss attributable to owners decreased by 143 million Hong Kong dollars, a year-on-year decrease of 14.3%, with a loss per share of 3.23 Hong Kong cents.
DIGITAL DOMAIN (00547) announced its financial performance for the year ended December 31, 2025, with revenue of HK$777 million, a 24.2% year-on-year increase. The company's attributable net loss was HK$257 million, a 14.3% decrease, with a loss per share of 3.23 HK cents.
The announcement stated that the loss for the year was mainly due to: the recognition of non-cash outflow expenses, including amortization and depreciation expenses; impairment losses on goodwill and intangible assets from a cash-generating unit amounting to HK$36.035 million (2024: Nil); fair value loss on financial assets measured at fair value through profit or loss of HK$37.059 million (2024: gain of HK$6.031 million); expenses related to share options granted during the year and settled by issuing shares with a value of HK$7.568 million; and operating losses from the media and entertainment segment.
Related Articles

China Glass (03300) announced a net loss attributable to equity shareholders of approximately RMB 4.893 billion in 2025, representing an increase of about 4.58 times year-on-year.

CITIC SEC: The value of energy security is highlighted, and public utilities are expected to benefit from reevaluation

SSY GROUP(02005): Upatinib has been approved by the China Food and Drug Administration for registration as an active pharmaceutical ingredient for use in marketed preparations.
China Glass (03300) announced a net loss attributable to equity shareholders of approximately RMB 4.893 billion in 2025, representing an increase of about 4.58 times year-on-year.

CITIC SEC: The value of energy security is highlighted, and public utilities are expected to benefit from reevaluation

SSY GROUP(02005): Upatinib has been approved by the China Food and Drug Administration for registration as an active pharmaceutical ingredient for use in marketed preparations.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


